NCT01669096View on ClinicalTrials.gov

Study in Healthy Adults to Evaluate Gene Activation After Vaccination With GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 21, 2012

Primary Completion Date

December 6, 2012

Study Completion Date

May 24, 2013

Conditions
Tuberculosis
Interventions
BIOLOGICAL

GSK Biologicals' investigational TB vaccine GSK 692342

2 doses administered intramuscularly according to a 0, 1 month schedule (Day 0 and Day 30), in the deltoid region of the arm

Trial Locations (1)

9000

GSK Investigational Site, Ghent

Sponsors

Lead Sponsor

GlaxoSmithKline

Collaborators (1)

Aeras
All Listed Sponsors
collaborator

Aeras

OTHER

lead

GlaxoSmithKline

INDUSTRY